Inside Nephrology: A Weekly Review
Nefrologia
The Rise of Targeted Kidney Therapies: Redefining Glomerulonephritis
Recent studies highlight a turning point in glomerulonephritis care. This episode reviews new data on C3G outcomes, CAR T-cell therapy for lupus nephritis, and emerging treatments like felzartamab, iptacopan, and SGLT2 inhibitors — marking a shift toward more personalized, targeted kidney therapies.
Bibliography
- Caravaca-Fontán F, et al. C3 glomerulopathy and immune complex MPGN: clinical patterns and outcomes. Nephron. 2025.
- Hu Z, et al. BCMA CAR T therapy induces remission in refractory lupus nephritis. Ann Rheum Dis. 2025.
- Floege J, et al. Felzartamab shows efficacy in IgA nephropathy (phase 2a trial). Kidney Int. 2025.
- Romagnani P. SGLT2 inhibitors in CKD: patient-specific effectiveness. Nephrol Dial Transplant. 2025.
- Chen J, et al. ANCA vasculitis with crescentic GN and thyroid carcinoma: case report. Medicine (Baltimore). 2025.
- Rovin BH, et al. Long-term voclosporin effects on renal histology in lupus nephritis. Arthritis Rheumatol. 2025.
- Ural Z, et al. Coronin-1A deficiency with IgM-dominant MPGN: rare case. CEN Case Rep. 2025.
- Kavanagh D, et al. Oral iptacopan effective in C3 glomerulopathy (phase 3 trial). Lancet. 2025.
- Kaynar K, et al. Membranous nephropathy in Sjögren’s disease. Reumatismo. 2025.
- Ogieuhi IJ, et al. ANCA-associated GN after COVID-19 vaccination: update. Cureus. 2025.
